Trigeminal Neuralgia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major trigeminal neuralgia markets reached a value of US$ 234.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 357.8 Million by 2034, exhibiting a growth rate (CAGR) of 3.92% during 2024-2034.
The trigeminal neuralgia market has been comprehensively analyzed in IMARC's new report titled "Trigeminal Neuralgia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Trigeminal neuralgia, also called tic douloureux, refers to a disorder that affects the trigeminal nerve, which is responsible for sending sensory information from the face to the brain. This disease is often characterized by sudden, severe, and intense facial pain (usually on one side of the face) that can last from a few seconds to several minutes. The pain can be triggered by simple actions, such as touching the face, brushing the teeth, or even talking. Individuals suffering from trigeminal neuralgia may experience muscle spasms, episodes of sharp, shooting or jabbing pain, a stabbing or electrical-type feeling, oversensitivity or uncomfortable tingling, etc. The diagnosis of this illness relies on the identification of clinical features, medical history, and a physical exam of the head and neck region. A neurological examination is further recommended, in which the healthcare provider touches and examines portions of the face to identify the location and triggering factors of the pain. Additionally, a high-resolution, thin-slice magnetic resonance imaging test that helps to rule out other causes of underlying indications is also utilized.
The rising cases of multiple sclerosis, which can cause deterioration of the body's main protective layer around the neuron, known as the myelin sheath, are primarily driving the trigeminal neuralgia market. In addition to this, the increasing incidences of nerve compression on account of facial injury, obesity, cervical foraminal narrowing, etc., are also propelling the market growth. Furthermore, the inflating adoption of anticonvulsant drugs, including carbamazepine and gabapentin, to control pain and lessen the symptoms of the disease is acting as another significant growth-inducing factor. Apart from this, the escalating application of microvascular decompression technique for identifying any blood vessels that may be contributing to nerve compression and treating the nerve to recover and return to a normal, pain-free condition is creating a positive outlook for the market. Additionally, the emerging popularity of deep brain stimulation therapy, which involves the implantation of electrodes within specific areas of the brain to drastically improve pain and boost the quality of life in patients, is expected to drive the trigeminal neuralgia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the trigeminal neuralgia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for trigeminal neuralgia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the trigeminal neuralgia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the trigeminal neuralgia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the trigeminal neuralgia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current trigeminal neuralgia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the trigeminal neuralgia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the trigeminal neuralgia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the trigeminal neuralgia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of trigeminal neuralgia across the seven major markets?
What is the number of prevalent cases (2018-2034) of trigeminal neuralgia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of trigeminal neuralgia by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of trigeminal neuralgia by type across the seven major markets?
How many patients are diagnosed (2018-2034) with trigeminal neuralgia across the seven major markets?
What is the size of the trigeminal neuralgia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of trigeminal neuralgia?
What will be the growth rate of patients across the seven major markets?
Trigeminal Neuralgia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for trigeminal neuralgia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the trigeminal neuralgia market?
What are the key regulatory events related to the trigeminal neuralgia market?
What is the structure of clinical trial landscape by status related to the trigeminal neuralgia market?
What is the structure of clinical trial landscape by phase related to the trigeminal neuralgia market?
What is the structure of clinical trial landscape by route of administration related to the trigeminal neuralgia market?
The trigeminal neuralgia market has been comprehensively analyzed in IMARC's new report titled "Trigeminal Neuralgia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Trigeminal neuralgia, also called tic douloureux, refers to a disorder that affects the trigeminal nerve, which is responsible for sending sensory information from the face to the brain. This disease is often characterized by sudden, severe, and intense facial pain (usually on one side of the face) that can last from a few seconds to several minutes. The pain can be triggered by simple actions, such as touching the face, brushing the teeth, or even talking. Individuals suffering from trigeminal neuralgia may experience muscle spasms, episodes of sharp, shooting or jabbing pain, a stabbing or electrical-type feeling, oversensitivity or uncomfortable tingling, etc. The diagnosis of this illness relies on the identification of clinical features, medical history, and a physical exam of the head and neck region. A neurological examination is further recommended, in which the healthcare provider touches and examines portions of the face to identify the location and triggering factors of the pain. Additionally, a high-resolution, thin-slice magnetic resonance imaging test that helps to rule out other causes of underlying indications is also utilized.
The rising cases of multiple sclerosis, which can cause deterioration of the body's main protective layer around the neuron, known as the myelin sheath, are primarily driving the trigeminal neuralgia market. In addition to this, the increasing incidences of nerve compression on account of facial injury, obesity, cervical foraminal narrowing, etc., are also propelling the market growth. Furthermore, the inflating adoption of anticonvulsant drugs, including carbamazepine and gabapentin, to control pain and lessen the symptoms of the disease is acting as another significant growth-inducing factor. Apart from this, the escalating application of microvascular decompression technique for identifying any blood vessels that may be contributing to nerve compression and treating the nerve to recover and return to a normal, pain-free condition is creating a positive outlook for the market. Additionally, the emerging popularity of deep brain stimulation therapy, which involves the implantation of electrodes within specific areas of the brain to drastically improve pain and boost the quality of life in patients, is expected to drive the trigeminal neuralgia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the trigeminal neuralgia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for trigeminal neuralgia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the trigeminal neuralgia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the trigeminal neuralgia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the trigeminal neuralgia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current trigeminal neuralgia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the trigeminal neuralgia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the trigeminal neuralgia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the trigeminal neuralgia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of trigeminal neuralgia across the seven major markets?
What is the number of prevalent cases (2018-2034) of trigeminal neuralgia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of trigeminal neuralgia by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of trigeminal neuralgia by type across the seven major markets?
How many patients are diagnosed (2018-2034) with trigeminal neuralgia across the seven major markets?
What is the size of the trigeminal neuralgia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of trigeminal neuralgia?
What will be the growth rate of patients across the seven major markets?
Trigeminal Neuralgia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for trigeminal neuralgia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the trigeminal neuralgia market?
What are the key regulatory events related to the trigeminal neuralgia market?
What is the structure of clinical trial landscape by status related to the trigeminal neuralgia market?
What is the structure of clinical trial landscape by phase related to the trigeminal neuralgia market?
What is the structure of clinical trial landscape by route of administration related to the trigeminal neuralgia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TRIGEMINAL NEURALGIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 TRIGEMINAL NEURALGIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TRIGEMINAL NEURALGIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 TRIGEMINAL NEURALGIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TRIGEMINAL NEURALGIA - UNMET NEEDS
10 TRIGEMINAL NEURALGIA - KEY ENDPOINTS OF TREATMENT
11 TRIGEMINAL NEURALGIA - MARKETED PRODUCTS
11.1 List of Trigeminal Neuralgia Marketed Drugs Across the Top 7 Markets
11.1.1 Carbatrol (Carbamazepine controlled release) - Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 TRIGEMINAL NEURALGIA - PIPELINE DRUGS
12.1 List of Trigeminal Neuralgia Pipeline Drugs Across the Top 7 Markets
12.1.1 IP 2015 - Initiator Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Basimglurant - Noema Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Rimegepant - Pfizer
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. TRIGEMINAL NEURALGIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TRIGEMINAL NEURALGIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TRIGEMINAL NEURALGIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Trigeminal Neuralgia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Trigeminal Neuralgia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Trigeminal Neuralgia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Trigeminal Neuralgia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Trigeminal Neuralgia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Trigeminal Neuralgia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Trigeminal Neuralgia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Trigeminal Neuralgia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Trigeminal Neuralgia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Trigeminal Neuralgia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Trigeminal Neuralgia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Trigeminal Neuralgia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Trigeminal Neuralgia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Trigeminal Neuralgia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Trigeminal Neuralgia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Trigeminal Neuralgia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Trigeminal Neuralgia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Trigeminal Neuralgia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Trigeminal Neuralgia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Trigeminal Neuralgia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Trigeminal Neuralgia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Trigeminal Neuralgia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Trigeminal Neuralgia - Access and Reimbursement Overview
16 TRIGEMINAL NEURALGIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TRIGEMINAL NEURALGIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TRIGEMINAL NEURALGIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TRIGEMINAL NEURALGIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 TRIGEMINAL NEURALGIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TRIGEMINAL NEURALGIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 TRIGEMINAL NEURALGIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TRIGEMINAL NEURALGIA - UNMET NEEDS
10 TRIGEMINAL NEURALGIA - KEY ENDPOINTS OF TREATMENT
11 TRIGEMINAL NEURALGIA - MARKETED PRODUCTS
11.1 List of Trigeminal Neuralgia Marketed Drugs Across the Top 7 Markets
11.1.1 Carbatrol (Carbamazepine controlled release) - Takeda
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 TRIGEMINAL NEURALGIA - PIPELINE DRUGS
12.1 List of Trigeminal Neuralgia Pipeline Drugs Across the Top 7 Markets
12.1.1 IP 2015 - Initiator Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Basimglurant - Noema Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Rimegepant - Pfizer
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. TRIGEMINAL NEURALGIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TRIGEMINAL NEURALGIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TRIGEMINAL NEURALGIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Trigeminal Neuralgia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Trigeminal Neuralgia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Trigeminal Neuralgia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Trigeminal Neuralgia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Trigeminal Neuralgia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Trigeminal Neuralgia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Trigeminal Neuralgia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Trigeminal Neuralgia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Trigeminal Neuralgia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Trigeminal Neuralgia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Trigeminal Neuralgia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Trigeminal Neuralgia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Trigeminal Neuralgia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Trigeminal Neuralgia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Trigeminal Neuralgia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Trigeminal Neuralgia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Trigeminal Neuralgia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Trigeminal Neuralgia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Trigeminal Neuralgia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Trigeminal Neuralgia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Trigeminal Neuralgia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Trigeminal Neuralgia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Trigeminal Neuralgia - Access and Reimbursement Overview
16 TRIGEMINAL NEURALGIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TRIGEMINAL NEURALGIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TRIGEMINAL NEURALGIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
